Crinetics Pharmaceuticals Inc. (CRNX) is a clinical-stage biopharmaceutical company that develops innovative therapeutics for endocrine diseases and endocrine-related tumors. The company's lead product candidate is called paltusotine, a nonpeptide, oral selective somatostatin receptor type 2 agonist designed for the treatment of acromegaly, an orphan disease caused by excess growth hormone secretion. Paltusotine has completed Phase 2 clinical trials, with the company expecting to initiate a Phase 3 trial in the second half of 2021. The company's other product candidates include CRN04777, an oral nonpeptide somatostatin agonist for the treatment of congenital hyperinsulinism, and CRN04894, an oral selective nonpeptide adrenocorticotropic hormone (ACTH) antagonist for the treatment of Cushing's disease. The company has partnerships with firms like Eli Lilly and Company and Roche. Crinetics Pharmaceuticals is headquartered in San Diego, California, and trades on the NASDAQ stock exchange.
Crinetics Pharmaceuticals Inc. (CRNX) is a clinical-stage biopharmaceutical company that develops innovative therapeutics for endocrine diseases and endocrine-related tumors. The company's lead product candidate is called paltusotine, a nonpeptide, oral selective somatostatin receptor type 2 agonist designed for the treatment of acromegaly, an orphan disease caused by excess growth hormone secretion. Paltusotine has completed Phase 2 clinical trials, with the company expecting to initiate a Phase 3 trial in the second half of 2021. The company's other product candidates include CRN04777, an oral nonpeptide somatostatin agonist for the treatment of congenital hyperinsulinism, and CRN04894, an oral selective nonpeptide adrenocorticotropic hormone (ACTH) antagonist for the treatment of Cushing's disease. The company has partnerships with firms like Eli Lilly and Company and Roche. Crinetics Pharmaceuticals is headquartered in San Diego, California, and trades on the NASDAQ stock exchange.